Compositions and methods for expansion of embryonic hematopoietic stem cells
AssigneeFred Hutchinson Cancer Research Center
InventorsIrwin D. Bernstein, Brandon K. Hadland
Life of this patent
Estimating the term…
Loading patent…
AssigneeFred Hutchinson Cancer Research Center
InventorsIrwin D. Bernstein, Brandon K. Hadland
Estimating the term…
The present invention relates to methods, kits and compositions for expansion of embryonic hematopoietic stem cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGFp pathway. Also provided herein are methods for expanding embryonic hematopoietic stem cells using kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TOPβ pathway. The embryonic hematopoietic stem cells expanded using the disclosed kits, compositions and methods include cells derived from an embryo (e.g., aorta-gonad-mesonephros region of the embryo), embryonic stem cells, induced pluripotent stem cells, or reprogrammed cells of other types. The present invention also relates to administering the embryonic hematopoietic stem cells expanded using a combination of a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGFp pathway to a patient for short-term and/or long-term in vivo repopulation benefits.
A method of expanding embryonic hematopoietic stem cells, comprising culturing the embryonic hematopoietic stem cells ex vivo in the presence of a composition comprising a Delta or Jagged Notch agonist;
A method of expanding human embryonic hematopoietic stem cells, comprising culturing the human embryonic hematopoietic stem cells ex vivo on a solid phase coated with Delta1ext-IgG and CH-296, and in the presence of a fluid medium comprising SB431542, SCF, Flt-3, IL-3, TPO, IL-11, and IL-6;
Dependencies are inferred from the claim text.